A Phase 2 interventional study of Placebo and CP-690,550 in Crohn's Disease, sponsored by Pfizer. Completed at 140 sites in 18 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-04-28.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Crohn Disease by Pfizer — none open to participants now, none under way, none of them phase 3. Crohn Disease · Pfizer.
Among the 17 studies in Crohn Disease by Pfizer, this one is the 2nd largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2011, is one of 9 in phase 2, and was the 7th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →None of the 17 studies in Crohn Disease by Pfizer is open now. The open studies under Crohn Disease, anywhere →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 1
First in 2002; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 280 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 180 across the 11 interventional studies, 1,431 across the 5 observational. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Crohn Disease by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease. The study hypothesis is that at least one dose of the tested drug is more effective than placebo (inactive drug).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: CP-690,550
Drug: CP-690,550
oral tablets twice daily
oral tablets twice daily
oral tablets twice daily
Percentage of Participants in Clinical Remission (as Defined by a Crohn's Disease Activity Index [CDAI] Score of Less Than [<] 150 Points) at Week 8
Clinical remission was a CDAI \< 150 points. CDAI is a composite index consisting of a weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's diary kept while on study. CDAI scores range from 0 to approximately 600, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
Time frame: Week 8
Percentage of Participants in Clinical Remission (CDAI <150) at Weeks 2 and 4
Clinical remission was a CDAI \<150 points. CDAI is a composite index consisting of a weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's diary kept while on study. CDAI scores range from 0 to approximately 600, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
Time frame: Weeks 2 and 4
Percentage of Participants Achieving Clinical Response-70 (as Defined by a Decrease in CDAI Score of at Least 70 Points From Baseline) at Weeks 2, 4, and 8
Clinical response-70 was defined as a reduction in CDAI score from baseline of at least 70 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
Time frame: Baseline, Weeks 2, 4, and 8
Percentage of Participants Achieving Clinical Response-100 (as Defined by a Decrease in CDAI Score of at Least 100 Points From Baseline) at Weeks 2, 4, and 8
Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
Time frame: Baseline, Weeks 2, 4, and 8
Percentage of Participants Achieving Either Clinical Response-100 or Clinical Remission (CDAI<150) at Weeks 2, 4, and 8
Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. Clinical remission was a CDAI \< 150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
Time frame: Baseline, Weeks 2, 4, and 8
CDAI Scores at Weeks 2, 4, and 8
CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
Time frame: Weeks 2, 4, and 8
C-Reactive Protein (CRP) Serum Concentrations at Weeks 2, 4, and 8
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Time frame: Weeks 2, 4, and 8
Calprotectin Fecal Concentrations at Weeks 2, 4, and 8
Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation.
Time frame: Weeks 2, 4, and 8
Tofacitinib Plasma Concentrations From 0 to 2 Hours Post Dose on Day 1 and at Week 8/Early Termination (ET) Visit
Plasma samples were collected from participants for the determination of tofacitinib concentrations. Only samples from tofacitinib-treated participants were subsequently analyzed. Plasma concentration data are summarized by nominal sample collection times specified in the protocol, and actual sample collection times may be different.
Time frame: Pre-dose, 20 minutes, 40 minutes, 1 hour, and 2 to 3 hours post-dose on Day 1 and Week 8/ET visit
Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Baseline and Week 8/ET Visit
The IBDQ is a psychometrically validated patient reported outcome (PRO) instrument for measuring disease-specific quality of life (QOL) in participants with inflammatory bowel disease (IBD). IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items are grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: bowel symptoms 10 to 70; systemic symptoms 5 to 35; emotional function 12 to 84; social function 5 to 35. For each domain, a higher score indicates better QOL. Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QOL. Positive change in total score indicated improvement in QOL.
Time frame: Baseline, Week 8/ET visit
Change From Baseline IBDQ Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Week 8/ET Visit Using Analysis of Covariance (ANCOVA)
IBDQ is a validated PRO instrument for measuring QOL in IBD consisting of 32 items scored from 1 (worst response) to 7 (best response). 32 items are grouped into 4 domains scored as follows: bowel symptoms 10 - 70; systemic symptoms 5 - 35; emotional function 12 - 84; social function 5 - 35. For each domain, higher score indicates better QOL. Total score is the sum of each item score, \& ranged from 32 to 224 with a higher score indicating better QOL. Positive change in total score indicated improvement in QOL. Adjusted means were derived from an ANCOVA model with baseline value as covariate, treatment group \& prior use of anti-tumor necrosis factor (TNF) alpha (α) treatments as factors. The 15 mg BID treatment group was closed to further enrolment early in the study by Protocol Amendment 5 after only 16 participants were enrolled in this group. Therefore, the efficacy analysis was not performed for this group as the results may be difficult to interpret due to the small sample size.
Time frame: Baseline, Week 8/ET visit
Percentage of Participants With an IBDQ Total Score of Greater Than or Equal to (≥) 170 at Week 8/ET Visit
The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QOL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QOL. Positive change in total score indicated improvement in QOL.
Time frame: Week 8/ET visit
Percentage of Participants With ≥16 Point Increase From Baseline in IBDQ Total Score at Week 8/ET Visit
The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QOL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QOL. Positive change in total score indicated improvement in QOL.
Time frame: Week 8/ET visit
Percentage of Participants With a Response to the Patient-Reported Treatment Impact Assessment (PRTI) at Week 8/ET Visit by Category
The IBD Patient Reported Treatment Impact Modified (PRTI) questionnaire comprises 3 individual questions administered to the participant: participant satisfaction with study treatment; participant preference for study drug over prior treatment (this question on participant preference for study drug is prefaced by a simple question of previous treatment/s for IBD received in order to place the preference question into context) and participant willingness to re-use the study treatment again. Each of these questions (except the question on previous treatment, which is informational only) is scored on a 5 point Likert scale. PSA = Patient Satisfaction Assessment; PPTA = Patient Previous Treatment Assessment; PPA = Patient Preference Assessment; PWA = Patient Willingness Assessment.
Time frame: Week 8/ET visit
Short Form 36 Health Survey (SF-36) Component and Domain Scores at Baseline and Week 8/ET Visit
The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based T scores for both the SF-36 version 2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QOL.
Time frame: Baseline, Week 8/ET visit
Change From Baseline SF-36 Component and Domain Scores at Week 8/ET Visit Using ANCOVA
The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based T scores for both the SF-36 version 2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QOL. Adjusted means were derived from the ANCOVA model with baseline value as a covariate, treatment group and prior use of anti-TNF alpha treatments as factors. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
Time frame: Baseline, Week 8/ET visit
EuroQoL 5 Dimensions Questionnaire (EQ-5D) Utility Scores at Baseline and Week 8/ET Visit
EQ-5D is a participant rated questionnaire to assess health-related QoL in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range from -0.594 to 1.000; a higher score indicates a better health state.
Time frame: Baseline, Week 8/ET visit
Change From Baseline EQ-5D Utility Scores at Week 8/ET Visit Using ANCOVA
EQ-5D is a participant rated questionnaire to assess health-related QoL via a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain \& discomfort, anxiety \& depression; 1 = better health state (no problems); 3 = worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain. Score is transformed to a total score ranging from -0.594 to 1.000; higher score indicates better health state. Adjusted means were derived from the ANCOVA model with baseline value as a covariate, treatment group \& prior use of anti-TNFα treatments as factors. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
Time frame: Baseline, Week 8/ET visit
EQ-5D Visual Analogue Scale (VAS) Scores at Baseline and Week 8/ET Visit
EQ-5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.
Time frame: Baseline, Week 8/ET visit
Change From Baseline EQ-5D VAS Scores at Week 8/ET Visit Using ANCOVA
EQ-5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. Adjusted means were derived from the ANCOVA model with baseline value as a covariate, treatment group \& prior use of anti-TNF alpha treatments as factors. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
Time frame: Baseline, Week 8/ET visit
| Milestone | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID |
|---|---|---|---|---|
| Started | 91 | 86 | 86 | 16 |
| Completed | 73 | 74 | 74 | 15 |
| Not completed | 18 | 12 | 12 | 1 |
| Withdrew: Adverse event | 2 | 1 | 5 | 0 |
| Withdrew: Did not meet entrance criteria | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 6 | 6 | 4 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 6 | 4 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 2 | 0 |
Clinical remission was a CDAI \< 150 points. CDAI is a composite index consisting of a weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's diary kept while on study. CDAI scores range from 0 to approximately 600, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
| Percentage of Participants | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Percentage of Participants in Clinical Remission (as Defined by a Crohn's Disease Activity Index [CDAI] Score of Less Than [<] 150 Points) at Week 8 | 36.67 (26.75 to 47.49) | 43.53 (32.80 to 54.72) | 43.02 (32.39 to 54.15) |
Clinical remission was a CDAI \<150 points. CDAI is a composite index consisting of a weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's diary kept while on study. CDAI scores range from 0 to approximately 600, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
| Percentage of Participants | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Week 2 | 10.00 (4.68 to 18.14) | 9.41 (4.15 to 17.71) | 9.30 (4.10 to 17.51) |
| Week 4 | 21.11 (13.21 to 30.99) | 24.71 (15.99 to 35.25) | 22.09 (13.86 to 32.33) |
Clinical response-70 was defined as a reduction in CDAI score from baseline of at least 70 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
| Percentage of Participants | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Week 2 | 37.78 (27.77 to 48.62) | 47.06 (36.13 to 58.19) | 44.19 (33.48 to 55.30) |
| Week 4 | 50.00 (39.27 to 60.73) | 57.65 (46.45 to 68.30) | 56.98 (45.85 to 67.61) |
| Week 8 | 62.22 (51.38 to 72.23) | 76.47 (66.03 to 85.00) | 74.42 (63.87 to 83.22) |
Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
| Percentage of Participants | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Week 2 | 23.33 (15.06 to 33.43) | 34.12 (24.18 to 45.20) | 32.56 (22.84 to 43.52) |
| Week 4 | 37.78 (27.77 to 48.62) | 48.24 (37.26 to 59.34) | 45.35 (34.58 to 56.45) |
| Week 8 | 54.44 (43.60 to 64.98) | 70.59 (59.71 to 79.98) | 68.60 (57.70 to 78.19) |
Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. Clinical remission was a CDAI \< 150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
| Percentage of Participants | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Week 2 | 24.44 (16.00 to 34.64) | 34.12 (24.18 to 45.20) | 32.56 (22.84 to 43.52) |
| Week 4 | 38.89 (28.79 to 49.74) | 49.41 (38.39 to 60.48) | 46.51 (35.68 to 57.59) |
| Week 8 | 55.56 (44.70 to 66.04) | 71.76 (60.96 to 81.00) | 69.77 (58.92 to 79.21) |
CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
| Score on a scale | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID |
|---|---|---|---|---|
| Week 2 (n=85, 78, 77, 16) | 258.04 ± 89.79 | 237.60 ± 67.87 | 241.21 ± 75.27 | 270.31 ± 90.78 |
| Week 4 (n=81, 78, 71, 15) | 228.65 ± 102.01 | 213.38 ± 86.04 | 203.58 ± 86.69 | 228.27 ± 103.01 |
| Week 8 (n=80, 77, 75, 15) | 194.90 ± 111.88 | 162.77 ± 87.67 | 159.08 ± 81.30 | 172.47 ± 119.28 |
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
| Milligrams per liter (mg/L) | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID |
|---|---|---|---|---|
| Week 2 (n=89, 84, 81, 16) | 17.28 ± 23.07 | 8.26 ± 11.40 | 8.56 ± 14.03 | 7.89 ± 9.42 |
| Week 4 (n=83, 82, 78, 16) | 18.94 ± 31.26 | 8.17 ± 10.60 | 9.48 ± 21.35 | 10.33 ± 16.80 |
| Week 8 (n=80, 77, 74, 15) | 18.12 ± 26.42 | 9.49 ± 15.33 | 6.55 ± 11.00 | 5.77 ± 7.74 |
Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation.
| mg per kilogram (mg/kg) | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID |
|---|---|---|---|---|
| Week 2 (n=81, 76, 73, 16) | 492.95 ± 664.51 | 384.81 ± 342.90 | 403.35 ± 352.57 | 455.10 ± 461.87 |
| Week 4 (n=81, 82, 71, 16) | 493.26 ± 682.81 | 467.09 ± 377.65 | 359.30 ± 306.88 | 338.11 ± 391.65 |
| Week 8 (n=75, 66, 72, 14) | 428.45 ± 479.36 | 417.70 ± 336.75 | 385.66 ± 316.71 | 349.61 ± 365.37 |
Plasma samples were collected from participants for the determination of tofacitinib concentrations. Only samples from tofacitinib-treated participants were subsequently analyzed. Plasma concentration data are summarized by nominal sample collection times specified in the protocol, and actual sample collection times may be different.
| nanograms per milliliter | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID |
|---|---|---|---|
| Day 1, 0 hours (n=83, 83, 16) | 0.006687 ± 0.049144 | 1.193 ± 9.0312 | NA ± NA |
| Day 1, 20 minutes (n=82, 83, 16) | 27.44 ± 27.335 | 62.28 ± 60.795 | 65.83 ± 63.232 |
| Day 1, 40 minutes (n=82, 81, 16) | 41.03 ± 24.210 | 84.61 ± 47.470 | 151.4 ± 61.288 |
| Day 1, 1 hour (n=83, 83, 16) | 41.22 ± 18.432 | 82.48 ± 40.782 | 149.9 ± 42.220 |
| Day 1, 2 hours (n=83, 82, 16) | 31.85 ± 12.442 | 70.01 ± 24.838 | 106.1 ± 26.661 |
| Week 8/ET, 0 hours (n=78, 72, 13) | 4.216 ± 7.1089 | 11.57 ± 21.453 | 23.89 ± 45.837 |
| Week 8/ET, 20 minutes (n=70, 70, 12) | 25.89 ± 21.485 | 71.14 ± 54.969 | 127.6 ± 89.861 |
| Week 8/ET, 40 minutes (n=70, 69, 12) | 37.75 ± 23.891 | 93.09 ± 46.471 | 148.7 ± 58.948 |
| Week 8/ET, 1 hour (n=70, 69, 12) | 37.47 ± 21.384 | 83.14 ± 35.100 | 144.7 ± 48.137 |
| Week 8/ET, 2 hours (n=72, 70, 13) | 27.61 ± 15.742 | 62.38 ± 27.505 | 92.03 ± 27.806 |
The IBDQ is a psychometrically validated patient reported outcome (PRO) instrument for measuring disease-specific quality of life (QOL) in participants with inflammatory bowel disease (IBD). IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items are grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: bowel symptoms 10 to 70; systemic symptoms 5 to 35; emotional function 12 to 84; social function 5 to 35. For each domain, a higher score indicates better QOL. Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QOL. Positive change in total score indicated improvement in QOL.
| Score on a scale | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID |
|---|---|---|---|---|
| IBDQ Total Score, Baseline | 118.50 ± 28.48 | 117.89 ± 27.98 | 113.67 ± 28.45 | 124.19 ± 26.97 |
| IBDQ Total Score, Week 8/ET | 144.99 ± 37.97 | 159.14 ± 35.39 | 156.64 ± 36.66 | 159.00 ± 47.98 |
| Bowel Function Score, Baseline | 37.78 ± 8.17 | 37.39 ± 9.37 | 36.29 ± 7.72 | 37.50 ± 9.78 |
| Bowel Function Score, Week 8/ET | 45.76 ± 12.19 | 50.94 ± 11.02 | 50.69 ± 11.02 | 52.50 ± 13.81 |
| Emotional Status Score, Baseline | 45.88 ± 13.04 | 45.34 ± 13.27 | 44.55 ± 13.27 | 47.25 ± 10.41 |
| Emotional Status Score, Week 8/ET | 56.31 ± 14.39 | 59.54 ± 13.78 | 58.32 ± 14.71 | 57.25 ± 20.07 |
| Systemic Symptoms Score, Baseline | 15.22 ± 5.24 | 15.58 ± 4.36 | 14.60 ± 4.78 | 16.44 ± 5.35 |
| Systemic Symptoms Score, Week 8/ET | 19.70 ± 6.51 | 22.24 ± 6.30 | 21.80 ± 6.27 | 22.88 ± 7.05 |
| Social Function Score, Baseline | 19.62 ± 7.28 | 19.48 ± 6.62 | 18.23 ± 7.09 | 23.00 ± 6.29 |
| Social Function Score, Week 8/ET | 23.23 ± 8.47 | 26.43 ± 7.57 | 25.83 ± 7.80 | 26.38 ± 9.58 |
IBDQ is a validated PRO instrument for measuring QOL in IBD consisting of 32 items scored from 1 (worst response) to 7 (best response). 32 items are grouped into 4 domains scored as follows: bowel symptoms 10 - 70; systemic symptoms 5 - 35; emotional function 12 - 84; social function 5 - 35. For each domain, higher score indicates better QOL. Total score is the sum of each item score, \& ranged from 32 to 224 with a higher score indicating better QOL. Positive change in total score indicated improvement in QOL. Adjusted means were derived from an ANCOVA model with baseline value as covariate, treatment group \& prior use of anti-tumor necrosis factor (TNF) alpha (α) treatments as factors. The 15 mg BID treatment group was closed to further enrolment early in the study by Protocol Amendment 5 after only 16 participants were enrolled in this group. Therefore, the efficacy analysis was not performed for this group as the results may be difficult to interpret due to the small sample size.
| Score on a scale | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| IBDQ Total Score | 26.58 ± 3.76 | 41.20 ± 3.90 | 40.05 ± 3.90 |
| Bowel Function Score | 8.36 ± 1.23 | 13.76 ± 1.28 | 13.88 ± 1.28 |
| Emotional Status Score | 10.33 ± 1.37 | 13.87 ± 1.42 | 12.54 ± 1.43 |
| Systemic Symptoms Score | 4.41 ± 0.66 | 6.70 ± 0.69 | 6.68 ± 0.69 |
| Social Function Score | 3.68 ± 0.79 | 7.03 ± 0.82 | 6.95 ± 0.82 |
The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QOL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QOL. Positive change in total score indicated improvement in QOL.
| Percentage of Participants | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID |
|---|---|---|---|---|
| Percentage of Participants With an IBDQ Total Score of Greater Than or Equal to (≥) 170 at Week 8/ET Visit | 26.1 | 45.2 | 43.2 | 43.8 |
The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QOL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QOL. Positive change in total score indicated improvement in QOL.
| Percentage of Participants | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID |
|---|---|---|---|---|
| Percentage of Participants With ≥16 Point Increase From Baseline in IBDQ Total Score at Week 8/ET Visit | 61.4 | 75.0 | 76.5 | 75.0 |
The IBD Patient Reported Treatment Impact Modified (PRTI) questionnaire comprises 3 individual questions administered to the participant: participant satisfaction with study treatment; participant preference for study drug over prior treatment (this question on participant preference for study drug is prefaced by a simple question of previous treatment/s for IBD received in order to place the preference question into context) and participant willingness to re-use the study treatment again. Each of these questions (except the question on previous treatment, which is informational only) is scored on a 5 point Likert scale. PSA = Patient Satisfaction Assessment; PPTA = Patient Previous Treatment Assessment; PPA = Patient Preference Assessment; PWA = Patient Willingness Assessment.
| Percentage of Participants | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID |
|---|---|---|---|---|
| PSA: Extremely dissatisfied | 17.0 | 6.0 | 7.4 | 6.3 |
| PSA: Dissatisfied | 10.2 | 9.6 | 6.2 | 0 |
| PSA: Neither satisfied nor dissatisfied | 25.0 | 19.3 | 16.0 | 25.0 |
| PSA: Satisfied | 40.9 | 45.8 | 43.2 | 25.0 |
| PSA: Extremely satisfied | 6.8 | 19.3 | 27.2 | 43.8 |
| PPTA: Injectable prescription medicines | 42.0 | 39.5 | 22.2 | 37.5 |
| PPTA: Prescription medicines taken by mouth | 37.5 | 44.4 | 56.8 | 43.8 |
| PPTA: Surgery | 2.3 | 2.5 | 0 | 0 |
| PPTA:Prescription medicines and surgery | 5.7 | 7.4 | 8.6 | 6.3 |
| PPTA: No treatment | 12.5 | 6.2 | 12.3 | 12.5 |
| PPA: Definitely prefer the drug I am receiving now | 33.0 | 42.2 | 48.1 | 56.3 |
| PPA: Slight preference for drug I'm receiving now | 19.3 | 27.7 | 22.2 | 25.0 |
| PPA: I have no preference either way | 28.4 | 19.3 | 13.6 | 18.8 |
| PPA: Slight preference for previous treatment | 9.1 | 2.4 | 7.4 | 0 |
| PPA: No, I definitely prefer my previous treatment | 10.2 | 8.4 | 8.6 | 0 |
| PWA: Would definitely want to use same drug again | 44.3 | 53.0 | 61.7 | 50.0 |
| PWA: Might want to use the same drug again | 11.4 | 24.1 | 17.3 | 37.5 |
| PWA: I am not sure | 20.5 | 10.8 | 8.6 | 6.3 |
| PWA: Might not want to use same drug again | 6.8 | 2.4 | 4.9 | 0 |
| PWA: Definitely not want to use same drug again | 17.0 | 9.6 | 7.4 | 6.3 |
The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based T scores for both the SF-36 version 2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QOL.
| Score on a Scale | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID |
|---|---|---|---|---|
| Physical component score, Baseline | 37.12 ± 7.66 | 38.49 ± 6.78 | 35.28 ± 8.49 | 37.09 ± 9.14 |
| Physical component score, Week 8/ET | 40.84 ± 9.23 | 45.23 ± 8.85 | 44.29 ± 9.41 | 47.01 ± 7.97 |
| Mental Component Score, Baseline | 36.50 ± 12.26 | 34.85 ± 11.68 | 35.84 ± 10.68 | 39.26 ± 11.85 |
| Mental Component Score, Week 8/ET | 42.46 ± 11.21 | 43.69 ± 12.15 | 43.65 ± 11.87 | 42.73 ± 16.37 |
| Physical Functioning Domain, Baseline | 43.73 ± 8.93 | 43.56 ± 8.81 | 41.36 ± 10.03 | 42.66 ± 9.04 |
| Physical Functioning Domain, Week 8/ET | 46.55 ± 8.93 | 49.68 ± 8.43 | 48.37 ± 8.78 | 49.57 ± 8.99 |
| Role Physical Domain, Baseline | 35.34 ± 9.94 | 36.36 ± 9.71 | 32.57 ± 10.92 | 37.68 ± 12.43 |
| Role Physical Domain, Week 8/ET | 39.92 ± 10.64 | 44.49 ± 11.52 | 42.84 ± 11.59 | 44.39 ± 13.18 |
| Bodily Pain Domain, Baseline | 34.69 ± 8.79 | 35.22 ± 8.44 | 33.32 ± 8.25 | 34.98 ± 8.23 |
| Bodily Pain Domain, Week 8/ET | 40.81 ± 10.43 | 44.68 ± 11.29 | 45.10 ± 10.41 | 47.61 ± 11.21 |
| General Health Domain, Baseline | 30.58 ± 7.21 | 31.37 ± 7.15 | 29.56 ± 7.52 | 32.08 ± 12.42 |
| General Health Domain, Week 8/ET | 34.36 ± 8.50 | 36.79 ± 8.53 | 37.19 ± 10.75 | 37.98 ± 13.51 |
| Vitality Domain, Baseline | 35.06 ± 9.70 | 34.66 ± 7.86 | 35.80 ± 9.05 | 37.55 ± 11.88 |
| Vitality Domain, Week 8/ET | 41.20 ± 11.45 | 45.22 ± 11.94 | 44.60 ± 12.53 | 48.77 ± 13.41 |
| Social Functioning Domain, Baseline | 34.71 ± 11.83 | 35.53 ± 11.69 | 33.83 ± 11.36 | 35.90 ± 10.61 |
| Social Functioning Domain, Week 8/ET | 40.02 ± 12.33 | 45.01 ± 11.79 | 43.46 ± 11.43 | 43.63 ± 14.94 |
| Role Emotional Domain, Baseline | 38.45 ± 13.98 | 37.20 ± 12.96 | 35.34 ± 13.23 | 39.12 ± 14.02 |
| Role Emotional Domain, Week 8/ET | 43.06 ± 12.43 | 44.77 ± 12.46 | 43.76 ± 11.94 | 42.90 ± 16.58 |
| Mental Health Domain, Baseline | 37.60 ± 12.30 | 35.95 ± 11.38 | 36.98 ± 11.09 | 41.27 ± 10.27 |
| Mental Health Domain, Week 8/ET | 43.75 ± 11.02 | 43.58 ± 11.67 | 44.76 ± 11.64 | 43.00 ± 15.96 |
The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based T scores for both the SF-36 version 2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QOL. Adjusted means were derived from the ANCOVA model with baseline value as a covariate, treatment group and prior use of anti-TNF alpha treatments as factors. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
| Score on a Scale | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Physical component score | 3.72 ± 0.927 | 7.28 ± 0.967 | 8.07 ± 0.956 |
| Mental Component Score | 6.47 ± 1.143 | 7.88 ± 1.178 | 7.13 ± 1.180 |
| Physical Functioning Domain | 3.01 ± 0.850 | 6.14 ± 0.876 | 5.59 ± 0.876 |
| Role Physical Domain | 5.02 ± 1.152 | 8.76 ± 1.191 | 8.95 ± 1.183 |
| Bodily Pain Domain | 6.41 ± 1.132 | 9.94 ± 1.174 | 11.10 ± 1.171 |
| General Health Domain | 3.62 ± 0.897 | 5.55 ± 0.937 | 7.03 ± 0.933 |
| Vitality Domain | 5.55 ± 1.190 | 9.84 ± 1.225 | 8.05 ± 1.233 |
| Social Functioning Domain | 5.25 ± 1.163 | 9.72 ± 1.206 | 8.66 ± 1.204 |
| Role Emotional Domain | 5.59 ± 1.222 | 7.28 ± 1.257 | 7.14 ± 1.260 |
| Mental Health Domain | 6.46 ± 1.100 | 7.05 ± 1.136 | 7.41 ± 1.134 |
EQ-5D is a participant rated questionnaire to assess health-related QoL in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range from -0.594 to 1.000; a higher score indicates a better health state.
| Score on a Scale | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID |
|---|---|---|---|---|
| Utility Score, Baseline | 0.56 ± 0.29 | 0.58 ± 0.26 | 0.49 ± 0.31 | 0.61 ± 0.24 |
| Utility Score, Week 8/ET | 0.64 ± 0.27 | 0.71 ± 0.28 | 0.71 ± 0.27 | 0.77 ± 0.30 |
EQ-5D is a participant rated questionnaire to assess health-related QoL via a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain \& discomfort, anxiety \& depression; 1 = better health state (no problems); 3 = worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain. Score is transformed to a total score ranging from -0.594 to 1.000; higher score indicates better health state. Adjusted means were derived from the ANCOVA model with baseline value as a covariate, treatment group \& prior use of anti-TNFα treatments as factors. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
| Score on a Scale | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Change From Baseline EQ-5D Utility Scores at Week 8/ET Visit Using ANCOVA | 0.08 ± 0.029 | 0.14 ± 0.030 | 0.16 ± 0.030 |
EQ-5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.
| mm | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID |
|---|---|---|---|---|
| VAS Score, Baseline | 46.83 ± 18.63 | 49.51 ± 18.03 | 42.74 ± 18.04 | 52.06 ± 24.11 |
| VAS Score, Week 8/ET | 58.32 ± 21.31 | 67.07 ± 19.39 | 65.77 ± 19.71 | 69.81 ± 21.11 |
EQ-5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. Adjusted means were derived from the ANCOVA model with baseline value as a covariate, treatment group \& prior use of anti-TNF alpha treatments as factors. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
| mm | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Change From Baseline EQ-5D VAS Scores at Week 8/ET Visit Using ANCOVA | 11.97 ± 2.166 | 19.56 ± 2.252 | 20.62 ± 2.222 |
Collected over SAEs were assessed from informed consent through and including 28 calendar days after last administration of study treatment (i.e. 11 weeks). Non-SAEs were recorded from time of first dose of study treatment through last participant visit (i.e. 15 weeks).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 3/91 (3.3%) | 43/91 (47.3%) |
| Tofacitinib 5 mg BID | — | 3/86 (3.5%) | 37/86 (43%) |
| Tofacitinib 10 mg BID | — | 10/86 (11.6%) | 42/86 (48.8%) |
| Tofacitinib 15 mg BID | — | 0/16 (0%) | 9/16 (56.3%) |
| Event | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID |
|---|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 1/91 | 0/86 | 3/86 | 0/16 |
| Anal fistulaGastrointestinal disorders | 0/91 | 0/86 | 1/86 | 0/16 |
| Small intestinal obstructionGastrointestinal disorders | 0/91 | 1/86 | 1/86 | 0/16 |
| Abdominal abscessInfections and infestations | 0/91 | 1/86 | 0/86 | 0/16 |
| Anal abscessInfections and infestations | 0/91 | 0/86 | 1/86 | 0/16 |
| GastroenteritisInfections and infestations | 0/91 | 1/86 | 0/86 | 0/16 |
| Pneumonia influenzalInfections and infestations | 0/91 | 0/86 | 1/86 | 0/16 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/91 | 0/86 | 1/86 | 0/16 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/91 | 0/86 | 1/86 | 0/16 |
| AnxietyPsychiatric disorders | 0/91 | 0/86 | 1/86 | 0/16 |
| Event | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID |
|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 5/91 | 1/86 | 2/86 | 4/16 |
| DiarrhoeaGastrointestinal disorders | 3/91 | 1/86 | 0/86 | 3/16 |
| Abdominal painGastrointestinal disorders | 5/91 | 3/86 | 7/86 | 2/16 |
| HeadacheNervous system disorders | 7/91 | 8/86 | 5/86 | 1/16 |
| NauseaGastrointestinal disorders | 8/91 | 5/86 | 7/86 | 0/16 |
| NasopharyngitisInfections and infestations | 3/91 | 3/86 | 6/86 | 0/16 |
| Crohn's diseaseGastrointestinal disorders | 6/91 | 5/86 | 4/86 | 1/16 |
| LymphadenopathyBlood and lymphatic system disorders | 0/91 | 0/86 | 0/86 | 1/16 |
| BradycardiaCardiac disorders | 0/91 | 0/86 | 0/86 | 1/16 |
| Ear painEar and labyrinth disorders | 0/91 | 0/86 | 1/86 | 1/16 |
Safety analysis set - included all participants who received at least one dose of study medication.
| Age, Continuous(Years) | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID | Total |
|---|---|---|---|---|---|
| Mean | 37.2 ± 11.7 | 40.2 ± 11.5 | 39.3 ± 13.7 | 41.3 ± 14.3 | 39.0 ± 12.4 |
| Sex: Female, Male(Participants) | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID | Total |
|---|---|---|---|---|---|
| Female | 60 | 32 | 47 | 7 | 146 |
| Male | 31 | 54 | 39 | 9 | 133 |
Showing the first 100 of 140 sites across 18 countries. Choose a country and city above to see the rest.
The record gives a start of Oct 2011, a primary completion of Feb 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib